Serotonergic involvement in the regulation of prolactin and vasoactive intestinal peptide mRNA expression in the rat anterior pituitary.
Serotonergic involvement in the regulation of prolactin and vasoactive intestinal peptide mRNA expression in the rat anterior pituitary.
复制标题
血清素参与调节大鼠垂体前叶催乳素和血管活性肠肽 mRNA 表达。
DOI：
10.1016/0303-7207(94)90168-6
复制
发表时间：
1994
影响因子：
4.1
通讯作者：
Carrillo,AJ
中科院分区：
文献类型：
--
作者：
Signs,SA;Liu,B;Wolford,J;Carrillo,AJ
这些研究检验了血清素 (5-HT) 对控制大鼠垂体前叶催乳素 (PRL) 和血管活性肠肽 (VIP) 信使 RNA 表达的贡献。每天给大鼠注射血清素生物合成前体 5-羟色氨酸（5-HTP；25 mg/kg q.i.d.），结果第 5 天垂体中 PRL mRNA 的表达增加了 50%，同时降低了 1.0 和 1.7kb VIP mRNA 转录物的水平。用 5-HTP 加儿茶酚胺生物合成抑制剂 α-甲基酪氨酸（α-MT；150 mg/kg q.d. × 2 天）或多巴胺受体拮抗剂氟哌啶醇（1.25 mg/kg b.i.d. × 5 天）共同治疗大鼠，导致垂体 PRL 信息水平增加，高于单独使用任一抗多巴胺能药物观察到的水平。相比之下，5-HTP 无法逆转多巴胺受体激动剂溴隐亭（2.5 mg/kg b.i.d. × 5 天）治疗引起的 PRL mRNA 表达抑制。 α-MT、氟哌啶醇和溴隐亭对垂体 VIP mRNA 表达均无显着影响。连续 14 天给予直接作用 5-HT 受体激动剂奎帕嗪（5 mg/kg，b.i.d.）导致垂体 PRL mRNA 水平在第 1 天显着增加，并在第 7 天和第 14 天达到比对照水平高出 90% 的平台。在奎帕嗪治疗的第 1 天，VIP mRNA 水平显着上升，但此后降至最低 22% (1.0 kb)，第 14 天时为对照的 52% (1.7 kb)。5-HT1 受体拮抗剂甲硫替平 (1 mg/kg t.i.d. × 3 天) 和 5-HT2 受体阻滞剂酮色林 (8 mg/kg t.i.d. × 3 天) 均无法减弱垂体 PRL mRNA 水平。突触前 5-HT 自身受体激动剂 5-MeODMT（6 mg/kg，三次，3 天）同样无效。然而，这些药物中的每一种都能显着降低垂体前叶中 VIP mRNA 的含量。这项研究表明，5-羟色胺系统有助于调节垂体前叶 PRL 和 VIP mRNA 表达。
These studies examined the contribution of serotonin (5-HT) to the control of prolactin (PRL) and vasoactive intestinal peptide (VIP) messenger RNA expression in rat anterior pituitary. Daily injection of rats with the biosynthetic precursor to serotonin, 5-hydroxytryptophan (5-HTP; 25 mg/kg q.i.d.), resulted on day 5 in a 50% increase in the expression of PRL mRNA in the pituitary while at the same time reducing the levels of both the 1.0 and 1.7kb VIP mRNA transcripts. Co-treatment of rats with 5-HTP plus the catecholamine biosynthesis inhibitor, α-methyl-tyrosine (α-MT; 150 mg/kg q.d. × 2 days), or the dopamine receptor antagonist haloperidol (1.25 mg/kg b.i.d. × 5 days), resulted in increases in pituitary PRL message levels that were greater than those observed with either anti-dopaminergic agent alone. In contrast, 5-HTP was unable to reverse the inhibition of PRL mRNA expression caused by treatment with the dopamine receptor agonist bromocriptine (2.5 mg/kg b.i.d. × 5 days). Neither α-MT, haloperidol nor bromocriptine had a significant effect on pituitary VIP mRNA expression. Administration of the direct-acting 5-HT receptor agonist quipazine (5 mg/kg, b.i.d.) for 14 consecutive days caused a significant increase in pituitary PRL mRNA levels on day 1 and reached a plateau of 90% above control levels on days 7 and 14. VIP mRNA levels rose significantly on day 1 of quipazine treatment but thereafter fell to a minimum of 22% (1.0 kb) and 52% (1.7 kb) of control by day 14. Both the 5-HT1receptor antagonist methiothepin (1 mg/kg t.i.d. × 3 days) and the 5-HT2receptor blocker ketanserin (8 mg/kg t.i.d. × 3 days) were unable to attenuate pituitary PRL mRNA levels. The presynaptic 5-HT autoreceptor agonist 5-MeODMT (6 mg/kg t.i.d. × 3 days) was equally ineffective. Each of these drugs, however, was able to produce marked reductions in VIP mRNA content in the anterior pituitary. This study indicates that the serotonergic system contributes to the regulation of anterior pituitary PRL and VIP mRNA expression.